Enterprise Therapeutics Ltd
Enterprise Therapeutics is a UK-based drug discovery company dedicated to developing novel therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD. They focus on creating disease-modifying therapies that target mucus congestion in the lungs to improve patient quality of life and extend lifespan. The company is backed by top tier venture capital investors and is based in the UK with offices at the University of Sussex Innovation Centre and in Blackfriars, London. They are developing muco-regulatory drugs to help respiratory patients breathe better and reduce lung infections, with a pipeline of low molecular weight compounds currently in clinical trials.
Industries
Nr. of Employees
small (1-50)
Enterprise Therapeutics Ltd
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB
Patents
Compounds with activity as inhibitors of the epithelial sodium channel (ENaC)
US-12037336-B2
View DetailsBis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives as ENaC inhibitors for treating respiratory diseases
US-11370778-B2
View Details
Compounds with activity as inhibitors of the epithelial sodium channel (ENaC)
US-12037336-B2
View DetailsBis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives as ENaC inhibitors for treating respiratory diseases
US-11370778-B2
View DetailsProducts
Clinical-stage inhaled ENaC modulator
A clinical-stage inhaled small-molecule ion-channel modulator designed to increase airway hydration and mucociliary clearance for muco-obstructive respiratory diseases; advanced into Phase 2 clinical testing.
Clinical-stage inhaled ENaC modulator
A clinical-stage inhaled small-molecule ion-channel modulator designed to increase airway hydration and mucociliary clearance for muco-obstructive respiratory diseases; advanced into Phase 2 clinical testing.
Services
End-to-end discovery activities for low-molecular-weight inhaled candidates, including phenotypic and target-based screening, medicinal chemistry optimisation, preclinical PK/PD and in vivo efficacy testing.
Development and validation of in vitro and in vivo assays (bronchospheres, ALI cultures, qPCR, immunohistochemistry, gamma-scintigraphy MCC) for target engagement and efficacy assessment.
Coordination and engagement with external clinical experts, physician advisors and academic collaborators to inform translational strategy and clinical trial design.
End-to-end discovery activities for low-molecular-weight inhaled candidates, including phenotypic and target-based screening, medicinal chemistry optimisation, preclinical PK/PD and in vivo efficacy testing.
Development and validation of in vitro and in vivo assays (bronchospheres, ALI cultures, qPCR, immunohistochemistry, gamma-scintigraphy MCC) for target engagement and efficacy assessment.
Coordination and engagement with external clinical experts, physician advisors and academic collaborators to inform translational strategy and clinical trial design.
Expertise Areas
- Respiratory drug discovery
- Inhaled therapeutics development
- Muco-regulatory target discovery and validation
- Ion channel pharmacology (ENaC and related targets)
Key Technologies
- Ion channel targeting (ENaC modulation)
- Inhalation/aerosol delivery and nebuliser administration
- 3D bronchosphere organoid cultures
- Air-liquid interface (ALI) primary airway epithelial cultures
News & Updates
Enterprise Therapeutics has dosed the first patient in a Phase 2 clinical trial for their novel therapy ETD001, aimed at treating cystic fibrosis.
The European Journal of Medicinal Chemistry published a paper on the medicinal chemistry of ETD001, a novel inhaled ENaC blocker developed by Enterprise Therapeutics for cystic fibrosis.
The US FDA granted rare pediatric disease designation to ETD001, Enterprise Therapeutics' investigational therapy for cystic fibrosis.
Enterprise Therapeutics has dosed the first patient in a Phase 2 clinical trial for their novel therapy ETD001, aimed at treating cystic fibrosis.
The European Journal of Medicinal Chemistry published a paper on the medicinal chemistry of ETD001, a novel inhaled ENaC blocker developed by Enterprise Therapeutics for cystic fibrosis.
The US FDA granted rare pediatric disease designation to ETD001, Enterprise Therapeutics' investigational therapy for cystic fibrosis.